Top 10 Peptide Clinical Trials to Watch in 2026
The pipeline of peptide therapeutics is more robust than ever, with a number of exciting new drugs in late-stage clinical development. This article highlights ten of the most anticipated peptide clinical trials to watch in 2026, with the potential to address a wide range of unmet medical needs.
1. Oral Semaglutide for Obesity (OASIS 1)
Novo Nordisk is conducting a Phase 3 clinical trial to evaluate the efficacy and safety of a higher dose of oral semaglutide for the treatment of obesity. If successful, this could provide a more convenient alternative to the injectable formulations of semaglutide (Wegovy) and other GLP-1 receptor agonists.
Key Details
- Sponsor: Novo Nordisk
- Indication: Obesity
- Mechanism of Action: GLP-1 receptor agonist
- Anticipated Completion: 2026
2. Tirzepatide for Heart Failure (SURMOUNT-HF)
Eli Lilly is investigating the potential of tirzepatide, a dual GIP/GLP-1 receptor agonist, for the treatment of heart failure with preserved ejection fraction (HFpEF) in patients with obesity. This trial could expand the use of tirzepatide beyond diabetes and weight loss.
Key Details
- Sponsor: Eli Lilly
- Indication: Heart Failure with Preserved Ejection Fraction (HFpEF)
- Mechanism of Action: Dual GIP/GLP-1 receptor agonist
- Anticipated Completion: 2026
3. Retatrutide for Obesity (TRIUMPH-3)
Eli Lilly is also developing retatrutide, a triple agonist that targets the GLP-1, GIP, and glucagon receptors. This novel peptide has shown even greater weight loss potential than tirzepatide in early-stage trials, and the results of the Phase 3 TRIUMPH-3 trial are highly anticipated.
Key Details
- Sponsor: Eli Lilly
- Indication: Obesity
- Mechanism of Action: Triple GLP-1/GIP/glucagon receptor agonist
- Anticipated Completion: 2026
4. CagriSema for Type 2 Diabetes (COMBINE-3)
Novo Nordisk is developing CagriSema, a co-formulation of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist). This combination therapy has the potential to provide even greater glycemic control and weight loss than either drug alone.
Key Details
- Sponsor: Novo Nordisk
- Indication: Type 2 Diabetes
- Mechanism of Action: Amylin analogue and GLP-1 receptor agonist
- Anticipated Completion: 2026
5. Bimagrumab for Obesity (ADVANCE-2)
Versanis Bio is developing bimagrumab, a monoclonal antibody that blocks the activin type II receptor, leading to increased muscle mass and decreased fat mass. This novel approach to weight loss could be a game-changer for patients with sarcopenic obesity.
Key Details
- Sponsor: Versanis Bio
- Indication: Obesity
- Mechanism of Action: Activin type II receptor blocker
- Anticipated Completion: 2026
6. LY3437943 for Chronic Kidney Disease
Eli Lilly is developing LY3437943, a GLP-1 receptor agonist, for the treatment of chronic kidney disease (CKD) in patients with type 2 diabetes. This trial could provide a new treatment option for a common and serious complication of diabetes.
Key Details
- Sponsor: Eli Lilly
- Indication: Chronic Kidney Disease (CKD)
- Mechanism of Action: GLP-1 receptor agonist
- Anticipated Completion: 2026
7. Dapiglutide for Type 2 Diabetes
Zealand Pharma is developing dapiglutide, a long-acting GLP-1/GLP-2 dual agonist, for the treatment of type 2 diabetes. This novel combination could provide both glycemic control and gut health benefits.
Key Details
- Sponsor: Zealand Pharma
- Indication: Type 2 Diabetes
- Mechanism of Action: Dual GLP-1/GLP-2 receptor agonist
- Anticipated Completion: 2026
8. Glepaglutide for Short Bowel Syndrome
Zealand Pharma is also developing glepaglutide, a long-acting GLP-2 analogue, for the treatment of short bowel syndrome (SBS). This condition can lead to malnutrition and dehydration, and glepaglutide has the potential to improve nutrient absorption and reduce the need for parenteral support.
Key Details
- Sponsor: Zealand Pharma
- Indication: Short Bowel Syndrome (SBS)
- Mechanism of Action: GLP-2 analogue
- Anticipated Completion: 2026
9. Relamorelin for Diabetic Gastroparesis
Allergan (now part of AbbVie) is developing relamorelin, a ghrelin agonist, for the treatment of diabetic gastroparesis. This condition can cause nausea, vomiting, and other debilitating symptoms, and relamorelin has the potential to improve gastric emptying and reduce symptoms.
Key Details
- Sponsor: Allergan (AbbVie)
- Indication: Diabetic Gastroparesis
- Mechanism of Action: Ghrelin agonist
- Anticipated Completion: 2026
10. ANAVEX2-73 for Alzheimer's Disease
Anavex Life Sciences is developing ANAVEX2-73, a small molecule activator of the sigma-1 receptor, for the treatment of Alzheimer's disease. While not a peptide, this drug is often discussed in the context of peptide and regenerative medicine, and the results of the Phase 3 trial are highly anticipated.
Key Details
- Sponsor: Anavex Life Sciences
- Indication: Alzheimer's Disease
- Mechanism of Action: Sigma-1 receptor activator
- Anticipated Completion: 2026
Comparison of Top Peptide Clinical Trials to Watch in 2026
| Drug | Sponsor | Indication | Mechanism of Action |
|---|---|---|---|
| Oral Semaglutide | Novo Nordisk | Obesity | GLP-1 receptor agonist |
| Tirzepatide | Eli Lilly | Heart Failure (HFpEF) | Dual GIP/GLP-1 receptor agonist |
| Retatrutide | Eli Lilly | Obesity | Triple GLP-1/GIP/glucagon receptor agonist |
| CagriSema | Novo Nordisk | Type 2 Diabetes | Amylin analogue & GLP-1 receptor agonist |
| Bimagrumab | Versanis Bio | Obesity | Activin type II receptor blocker |
| LY3437943 | Eli Lilly | Chronic Kidney Disease (CKD) | GLP-1 receptor agonist |
| Dapiglutide | Zealand Pharma | Type 2 Diabetes | Dual GLP-1/GLP-2 receptor agonist |
| Glepaglutide | Zealand Pharma | Short Bowel Syndrome (SBS) | GLP-2 analogue |
| Relamorelin | Allergan (AbbVie) | Diabetic Gastroparesis | Ghrelin agonist |
| ANAVEX2-73 | Anavex Life Sciences | Alzheimer's Disease | Sigma-1 receptor activator |
Key Takeaways
- The peptide pipeline is rich with innovative new drugs that have the potential to address a wide range of unmet medical needs.
- The focus of much of the late-stage development is on metabolic diseases, such as obesity and type 2 diabetes, with a number of new GLP-1 and multi-receptor agonists in the works.
- However, there are also a number of exciting new peptides in development for other conditions, such as heart failure, chronic kidney disease, and Alzheimer's disease.
- The results of these clinical trials will be eagerly anticipated in 2026 and beyond, and could have a major impact on the future of medicine.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
